Latest Biotechnology News

Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Proteomics International Laboratories has expanded its Share Purchase Plan offer after receiving applications exceeding $7.5 million, significantly increasing the number of new options issued.

Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

AdAlta Limited has successfully raised $1.1 million through a renounceable rights issue, positioning itself to advance key CAR-T licensing and immunotherapy projects. The capital injection underscores confidence from leadership and investors amid a transformative phase for the biotech company.

Opthea Limited faces a pivotal moment as four board members resign following disappointing Phase 3 trial results and a major workforce reduction. The company’s future hinges on ongoing funding negotiations amid trading suspensions.